Home
About
Publications Trends
Recent Publications
Expert Search
Archive
seizure prophylaxis:
Who Needs Seizure Prophylaxis?
Patients with brain tumors
: Primary brain tumors and metastatic brain lesions are common causes of seizures in cancer patients.
Post-surgical patients
: Those who have undergone neurosurgery for tumor resection are at risk.
Patients receiving radiation therapy
: Radiation to the brain can induce seizures.
Patients undergoing certain chemotherapies
: Some chemotherapeutic agents can lower the seizure threshold.
Frequently asked queries:
What is Seizure Prophylaxis?
Why is Seizure Prophylaxis Important in Cancer Patients?
Who Needs Seizure Prophylaxis?
When Should Seizure Prophylaxis Be Started?
What Medications Are Used for Seizure Prophylaxis?
What Are the Potential Side Effects of Seizure Prophylaxis Medications?
How is the Effectiveness of Seizure Prophylaxis Monitored?
Are There Non-Pharmacological Approaches to Seizure Prophylaxis?
What is the Role of Multidisciplinary Teams in Managing Seizure Prophylaxis?
What Resources Are Available for Developing Emotional Skills?
What are the Recommended Levels of Vitamin D?
Why Are Cancer Bills So High?
What is the Difference Between Supportive and Hospice Care?
What are Complex Carbohydrates?
Why Do Cancer Cells Prefer Aerobic Glycolysis?
Why is Clinical Cancer Research Important?
How Does PR Receptor Status Affect Treatment Options?
How is Metastasis Diagnosed?
What Role Do Patients Play in an MDT?
What is the Link Between Catechins and Cancer Prevention?
Top Searches
Brain Tumor
Breast cancer
cancer
Cancer Genomics
Chemotherapy
hepatocellular carcinoma
Lung Cancer
Nanotechnology
Non-Hodgkin’s Lymphoma
Radiation-Induced Malignancies
Follow Us
Facebook
Linkedin
Youtube
Instagram
Partnered Content Networks
Relevant Topics
4D Segmentation
Alopecia
Atlas-based Segmentation
Automated Segmentation
B-cell malignancies
biomarkers
Brain Tumor
Brain Tumor Segmentation
Breast cancer
cancer
Cancer Genome Atlas
Cancer genomics
Cancer treatment
CAR T-cell therapy
Carcinogenesis
cell adhesion
cell migration
chemotherapy
Chromatin remodeling genes
Chronic inflammation
CIAbimatoprost
Co-morbidity
Combination therapy
Copy number variations
cytokine release syndrome
Deep Learning
Diagnosis challenges
diffuse large B-cell lymphoma
DNA damage
docetaxel-cyclophosphamide
Drug delivery
epirubicin-cyclophosphamide
extracellular matrix
Fibrosis
Genetic alteration
Glioblastoma
Gold nanoparticles
Hepatocellular carcinoma
High Tumor
image-guided radiotherapy
Imaging Techniques
Immunosuppression
Immunotherapy
Integrative genomics
integrin inhibitors
Integrins
intensity-modulated radiation therapy
Keratinocyte
Lipid-based nanoparticles
liver cancer
long-term cancer risks
Lung cancer
Machine Learning
Magnetic Resonance Imaging
metastasis
methyltransferase
MRI
Multi-modal Imaging
Multidisciplinary care
Mutual exclusivity analysis
Nanoparticles
Nanotechnology
neoadjuvant radiotherapy
neurotoxicity
Next-generation sequencing
nnovative Biomarkers
Non-Hodgkin’s lymphoma
Novel Biomarkers for Brain Tumors
Novel Chemotherapy
Oncogenic transcription factors
oncological diseases
paclitaxel
Personalized medicine
Photobiomodulation therapy
Polymeric nanoparticles
portal vein tumor thrombus
Probabilistic Models
proton therapy
Radiation-induced malignancies
radiotherapy
refractory lymphoma
relapsed lymphoma
Risk factors
secondary cancer prevention
secondary cancers
Silver nanoparticles
stereotactic body radiation therapy
Targeted therapy
Tolerability
transarterial chemoembolization
Tuberculosis
tumor microenvironment
tumor progression
Voltage-gated sodium channels
Subscribe to our Newsletter
Stay updated with our latest news and offers related to Cancer.
Subscribe